Skip to main content
. 2018 Apr 17;12(6):788–798. doi: 10.1002/1878-0261.12172

Figure 6.

Figure 6

Cisplatin‐induced Noxa is regulated by ERK1 through ATF4 induction. (A) HN8 cells were treated with cisplatin (50 μm) or fenretinide (10 μm) for the indicated times. Equal amounts of the total extracts were used for immunoblot analysis with the indicated antibodies. (B) HN8 and HN12 cells were pretreated with a p38‐MAPK inhibitor, SB203580 (5 μm) for 30 min, and then treated with cisplatin for 16 h (50 μm for HN8 or 25 μm for HN12). Equal amounts of the total extracts were used for immunoblot analysis with the indicated antibodies. (C) HN8 and HN12 cells were pretreated with a MEK inhibitor, PD184352 (5 μm) for 30 min, and then treated with cisplatin for 16 h. Equal amounts of the total extracts were used for immunoblot analysis with the indicated antibodies. (D) HN12 cells were infected with lentiviruses encoding shRNA for nontargeting control, ERK1, or ERK2. Cells were treated with 25 μm of cisplatin for 16 h and equal amounts of the total extracts were used for immunoblot analysis with the indicated antibodies.